MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...

The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...

In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing ...

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.